Research into Peregrine Anticancer Compound Receives Grant
Posted on: Wednesday, 26 April 2006, 12:00 CDT
The US Department of Defense has awarded a new grant totaling $460,000 to the University of Texas Southwestern Medical Center to study Peregrine Pharmaceuticals' first-in-class anti-phospholipid agent bavituximab as an imaging and therapeutic agent for recurrent breast cancer.
In this new project, bavituximab, formally Tarvacin, will be labeled with radioactive isotopes to assess its potential as an imaging agent to identify tumor metastases and as a radio-immunoconjugate to treat metastatic disease. The drug is currently in a phase I clinical trial for advanced refractory solid tumors.
Bavituximab is a monoclonal antibody that binds selectively to cells that line tumor blood vessels. It has already shown promising activity in preclinical models of breast cancer. Previously published data in Cancer Research showed that a mouse equivalent of bavituximab in combination with docetaxel resulted in a 93% inhibition of human breast cancer growth in mouse cancer models.
"Data from this project could open the door for use of bavituximab as an agent to identity, measure and ultimately destroy the metastases that kill most cancer patients," said Steven King, president and CEO of Peregrine. "We are particularly pleased since this is the third competitive, peer-reviewed grant awarded by DOD with the potential to expand the clinical applications of bavituximab."
Despite recent medical advances in management of recurrent breast cancer, the prognosis remains poor for many patients and 40,000 women in the US die from metastatic breast disease each year.
Source: Datamonitor
Related Articles
- Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
- Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
- Further Testing With Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Cancer in Breast Cancer Patients, Changes Surgical Management
- NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
- QuantRx(R) Announces FluoroPharma, Inc. To Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
- FluoroPharma, Inc. To Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
- Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
- St. Louis Cancer and Breast Institute to Get New AccuBoost System for Breast Cancer
- Use of Hyperthermia Therapy in Treating Primary and Recurrent Breast Cancer Highlights Breast Cancer Congress
- 'Cure' for Cancer of Breast
 |
 |
User Comments (0)
RSS Feeds